Bluejay Therapeutics

Bluejay Therapeutics company information, Employees & Contact Information

Updated May 2026

Quick answer

Bluejay Therapeutics is a Biotechnology Research company and founded in 2020. It has approximately 34 employees on record. Contact data was last refreshed in May 2026. Find Bluejay Therapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

The mission of Bluejay Therapeutics is to develop innovative cures for infectious diseases with the first target indication of chronic HDV infection.

Company Details

Employees
34
Founded
2020
Address
San Francisco Bay Area, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
San Francisco Bay Area
Looking for a particular Bluejay Therapeutics employee's phone or email?

Bluejay Therapeutics Questions

News

Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy - GlobeNewswire

Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy GlobeNewswire

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D - Yahoo Finance

Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D Yahoo Finance

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis - GlobeNewswire

Bluejay Therapeutics raises $41 million in Series B round to drive clinical trials in chronic hepatitis GlobeNewswire

Bluejay Therapeutics Announces Data Presentations in - GlobeNewswire

Bluejay Therapeutics Announces Data Presentations in GlobeNewswire

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D - GlobeNewswire

Bluejay Therapeutics Enrolls First Patient in AZURE-2 Global Phase 3 Clinical Trial Evaluating Brelovitug (BJT-778) Compared to Hepcludex® (Bulevirtide) for Chronic Hepatitis D GlobeNewswire

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline - GlobeNewswire

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline GlobeNewswire

Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors - GlobeNewswire

Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors GlobeNewswire

Bluejay Therapeutics Presents Positive Preliminary BJT-778 - GlobeNewswire

Bluejay Therapeutics Presents Positive Preliminary BJT-778 GlobeNewswire

BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference - GlobeNewswire

BlueJay Therapeutics to Present at the 2nd Global IR@JPM Conference GlobeNewswire

Top Bluejay Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant